Massimo Loda, M.D.

Pathology - Molecular Genetic
Insurances Accepted

Please contact the doctor's office to verify that your insurance is accepted.

*Indicates this doctor is no longer accepting new patients with this insurance plan.

  • HMO
  • Medicare
  • PPO
  • EPO/POS
  • CHP
  • Blue Access
  • Blue Connection
  • EPO
  • HMO
  • Mediblue (Senior)
  • PPO
  • CBP
  • Medicaid
  • Medicare
  • Freedom
  • Liberty
  • Medicare Advantage
  • Metro/Core/Charter
  • Community Plan
  • Medicare
Biographical Info

Dr. Massimo Loda, an internationally renowned molecular pathologist, has been appointed chair of the Department of Pathology and Laboratory Medicine at Weill Cornell Medicine and pathologist-in-chief at NewYork-Presbyterian/Weill Cornell Medical Center.

Dr. Loda will helm the institutions’ pathology enterprise, which offers cutting-edge clinical and laboratory services and engages in high-impact science, with a strong focus on the biology of blood and solid tumor malignancies, including prostate cancer. In his new role and as a member of Weill Cornell Medicine’s Sandra and Edward Meyer Cancer Center, Dr. Loda will enhance the Department of Pathology and Laboratory Medicine’s diagnostic capabilities by introducing new techniques, including those that leverage computational pathology and large datasets to identify patterns and trends in disease. He will also seek to recruit outstanding new physicians and scientists to expand the department’s research portfolio and provide exemplary training to the next generation of pathologists. Dr. Loda will succeed Dr. Daniel Knowles, who has served as chair of the department for nearly 25 years.

Dr. Loda was recruited to Weill Cornell Medicine and NewYork-Presbyterian/Weill Cornell Medical Center from Dana-Farber Cancer Institute in Boston, where he is currently chair of the Department of Oncologic Pathology. He is also a professor of pathology at Harvard Medical School and chief of the Division of Translational and Molecular Oncologic Pathology at Brigham and Women’s Hospital.

An acclaimed physician-scientist with a focus on urologic oncology, Dr. Loda uses biochemical and genomic approaches to investigate the mechanisms by which prostate cancer hijacks cell metabolism to allow tumors to flourish.

Honors and Awards

MD, Summa cum laude Stowell-Orbison Award, University of Milan
US and

Canadian Academy of Pathology, Academic Achievement Clinical/Research, 1980

   

Stowell-Orbison Award, US and Canadian Academy of Pathology,


Clinical/Research, 1997

   

The Claudia Adams Barr Investigator in Cancer Research Award 
The Daland

Award, Dana-Farber Cancer Institute, Research and Clinical Innovation, 1998

   

The Daland Award, The New England Cancer Society, Research, 1998

   

Donald S. Coffey-CaP CURE Physician- Association for the Cure of Cancer of

the Prostate, Clinical/Research, 2003

   

Scientist Award, Nominated Officer (Knighthood), resident of the Republic

of Italy of the Order of the Star of Italy (Ufficiale dell’Ordine della Stella

d’Italia), 2015

   

Elected Member, Association of American Physicians, 2015

   

Board Certifications
American Board of Pathology
Clinical Expertise
Surgical Pathology
Languages
English
Education 
  • M.D.
    University of Milan Faculty of Medicine and Surgery (Italy)
    1980
Appointments 
  • Pathologist-in-Chief
    NewYork-Presbyterian Hospital
  • Chair of Pathology and Laboratory Medicine
    Weill Cornell Medical College, Cornell University
  • David D. Thompson Professor of Pathology
    Weill Cornell Medical College, Cornell University
  • Professor of Pathology and Laboratory Medicine
    Weill Cornell Medical College, Cornell University

Relationships and collaborations with for-profit and not-for profit organizations are of vital importance to our faculty because these exchanges of scientific information foster innovation. As experts in their fields, WCM physicians and scientists are sought after by many organizations to consult and educate. WCM and its faculty make this information available to the public, thus creating a transparent environment.

No External Relationships Reported